Patients with hs-cTnT ≥ 5 ng/L 3 months after COVID-19 had higher odds of having ≥ 1 abnormal finding on echocardiography or CMR than those with hs-cTnT < 5 ng/L: OR 5.14 [95% CI 1.5–17.5], P = 0.009, but this did not persist after adjusting for sex and age (OR 2.0 [95% CI 0.53–7.55), P = 0.31) (Table 3). This evidence concerns the gene TNNT2 and COVID-19.